Do Analysts Expect Emergent Biosolutions Inc (EBS) Stock to Rise After It Has Fallen -28.26% in a Month?

Wall Street is positive on Emergent Biosolutions Inc (EBS). On average, analysts give EBS a Hold rating. The average price target is $16.5, which means analysts expect the stock to add by 407.69% over the next twelve months. That average ranking earns EBS an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating EBS a Hold today. Find out what this means to you and get the rest of the rankings on EBS!

See Full EBS Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Emergent Biosolutions Inc Stock Today?

Emergent Biosolutions Inc (EBS) stock has fallen -5.52% while the S&P 500 is higher by 0.54% as of 12:32 PM on Friday, Sep 22. EBS is lower by -$0.19 from the previous closing price of $3.44 on volume of 569,916 shares. Over the past year the S&P 500 is up 15.84% while EBS is lower by -84.63%. EBS lost -$12.08 per share the over the last 12 months. Click Here to get the full Stock Report for Emergent Biosolutions Inc stock.